supported by grants from the Department of Science and Technology of Sichuan Province,China(No.23ZDYF2212,23ZDYF2098);the Foundation for Sichuan Provincial People's Hospital(Sichuan,China)(No.2022QN06);Medico-Engineering Cooperation Funds from the University of Electronic Science and Technology of China(No.ZYGX2021YGLH209)and 2022 Tianfu Qingcheng Project,China.
Glioma is a common tumor originating in the brain that has a high mortality rate.Temozolomide(TMZ)is the first-line treatment for high-grade gliomas.However,a large pro-portion of gliomas are resistant to TMZ,posing a...
supported by the grants from the Science and Technology Foundation of Guizhou Provincial Health and Family Planning Commission(Nos.gzwjkj2019-1-145,gzwkj2023-036,and Gzwjkj2017-1-026);the Postgraduate Research Foundation of Guizhou Province(QIAN JIAO HE YJSKYJJ[2021]206);the Guizhou Province Science and Technology Planning Project[Guizhou Genetic Basis-ZK[2023]General 326];the Guizhou Provincial Health Commission(No.gzwkj2023-036).
UBE2C is overexpressed in gliomas,and its overexpression has been reported to be correlated with the drug resistance of gliomas to some extent.In this study,we explore the role of UBE2C in regulating temozolomide(TMZ)...
supported by grants from the National Natural Science Foundation of China (82272659,82030087);the Science and Technology Innovation Program of Hunan Province (2022RC1210,2021RC3029);the Hunan Provincial Natural Science Foundation Project (2022JJ30073,2021JC0002).
Temozolomide(TMZ)represents a standard-of-care chemotherapeutic agent in glioblastoma(GBM).However,the development of drug resistance constitutes a significant hurdle in the treatment of malignant glioma.Although spec...
supported by National Natural Science Foundation of China(No.82003879);Project of Science and Technology Department of Sichuan Province(No.2023NSFSC1928;2023NSFSC1992);Young Elite Scientists Sponsorship Program by China Association for Science and Technology(No.CACM-2020-QNRC1-01);the Fundamental Research Funds for the central Universities.
Aim:Glioma accounts for 81%of all cancers of the nervous system cancers and presents one of the most drug-resistant malignancies,resulting in a relatively high mortality rate.Despite extensive efforts,the complete tre...
supported by Scientific Research Project of Education Department of Liaoning Province(Grant Number LJKZ0854).
Temozolomide(TMZ)resistance is a major obstacle in glioma treatment.Nuclear protein-1(NUPR1)is a regulator of glioma progression.This study investigated the mechanism of NUPR1 in TMZ resistance in hypoxiatreated gliom...